Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Type IV Collagen of Basal Lamina01:05

Type IV Collagen of Basal Lamina

Type IV collagen is a 400 nm long, network-forming collagen that acts as a barrier between the epithelial and endothelial cells. Type IV collagen  forms the backbone of the basement membrane by scaffolding with laminin, entactin, proteoglycans, and fibronectin. Apart from rendering structural support to the basement membrane, it also helps entail signaling potentials necessary for both pathological and physiological functions.
A type IV collagen molecule has six alpha chains which can exist in...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Intralumenal Vesicles and Multivesicular Bodies01:38

Intralumenal Vesicles and Multivesicular Bodies

Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacotherapies for Gaucher disease: what's new on the horizon?

Expert opinion on pharmacotherapy·2026
Same author

New evidence on the clinical, genetic, and biochemical bases of GBA1-Parkinson's disease: prospects for treatment.

The Lancet. Neurology·2026
Same author

Commentary on Prenatal Testing of a Complex Pathogenic Variant following Positive Carrier Screening for Gaucher Disease.

Clinical chemistry·2025
Same author

The Race to Salvage Glucocerebrosidase: Understanding Small-Molecule Therapies for GBA1-Associated Parkinsonism.

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

Bidirectional regulation of glycoprotein nonmetastatic melanoma protein B by β-glucocerebrosidase deficiency in <i>GBA1</i> isogenic dopaminergic neurons from a patient with Gaucher disease and parkinsonism.

bioRxiv : the preprint server for biology·2025
Same author

Dissecting the biological impact of <i>GBA1</i> mutations using multi-omics in an isogenic setting.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: May 31, 2026

Long-Term Catheterization of the Intestinal Lymph Trunk and Collection of Lymph in Neonatal Pigs
06:25

Long-Term Catheterization of the Intestinal Lymph Trunk and Collection of Lymph in Neonatal Pigs

Published on: March 5, 2016

Mucolipidosis type IV: an update.

Kazuyo Wakabayashi1, Ann Marie Gustafson, Ellen Sidransky

  • 1Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892-3708, USA.

Molecular Genetics and Metabolism
|July 19, 2011
PubMed
Summary

Mucolipidosis type IV (MLIV) is a rare genetic disorder affecting development and nerves. Increased awareness of its varied symptoms is crucial for accurate diagnosis and understanding this multi-system disease.

More Related Videos

Mucin Agarose Gel Electrophoresis: Western Blotting for High-molecular-weight Glycoproteins
09:24

Mucin Agarose Gel Electrophoresis: Western Blotting for High-molecular-weight Glycoproteins

Published on: June 14, 2016

Using Unfixed, Frozen Tissues to Study Natural Mucin Distribution
11:39

Using Unfixed, Frozen Tissues to Study Natural Mucin Distribution

Published on: September 21, 2012

Related Experiment Videos

Last Updated: May 31, 2026

Long-Term Catheterization of the Intestinal Lymph Trunk and Collection of Lymph in Neonatal Pigs
06:25

Long-Term Catheterization of the Intestinal Lymph Trunk and Collection of Lymph in Neonatal Pigs

Published on: March 5, 2016

Mucin Agarose Gel Electrophoresis: Western Blotting for High-molecular-weight Glycoproteins
09:24

Mucin Agarose Gel Electrophoresis: Western Blotting for High-molecular-weight Glycoproteins

Published on: June 14, 2016

Using Unfixed, Frozen Tissues to Study Natural Mucin Distribution
11:39

Using Unfixed, Frozen Tissues to Study Natural Mucin Distribution

Published on: September 21, 2012

Area of Science:

  • Genetics
  • Neuroscience
  • Cell Biology

Background:

  • Mucolipidosis type IV (MLIV) is a rare neurodevelopmental and neurodegenerative disorder.
  • Characterized by severe psychomotor delay, visual impairment, and achlorydria, with lysosomal inclusions in cells.
  • Caused by MCOLN1 gene mutations, encoding the mucolipin-1 TRP channel protein.

Purpose of the Study:

  • To provide an updated review of MLIV.
  • To enhance understanding of its ethnic distribution, clinical and laboratory findings, diagnosis, genetics, and treatment.
  • To improve recognition of MLIV, including milder variants and misdiagnosed cases.

Main Methods:

  • Literature review and synthesis of existing data on MLIV.
  • Analysis of clinical manifestations, diagnostic methods, and genetic basis.
  • Discussion of differential diagnosis and therapeutic approaches.

Main Results:

  • MLIV is a pan-ethnic disorder, though prevalent in Ashkenazi Jewish populations.
  • Misdiagnosis is common due to presentation mimicking cerebral palsy-like encephalopathy.
  • Milder MLIV variants often go unrecognized, suggesting a higher prevalence than appreciated.

Conclusions:

  • Enhanced awareness of MLIV's diverse manifestations is key to accurate diagnosis.
  • Understanding the full spectrum of MLIV aids in elucidating its pathogenesis.
  • Further research is needed to fully characterize this multi-system genetic disorder.